Ocular Melanoma

MYCN promotes ferroptosis in RB via xCT and transsulfuration pathways. Targeting the MYCN-xCT-transsulfuration axis may offer a novel therapeutic approach for MYCN-amplified RB.

Gene Set Enrichment Analysis confirms that lipid metabolic reprogramming, previously described in human tumors, is also a key feature of our model, validating its ability to recapitulate human disease biology. This study introduces a syngeneic preclinical model that mimics the immunosuppressive landscape of BAP1-deficient melanocytic tumors, enabling the development and optimization of new combination immunotherapies.

The exceptionally high prevalence of BAP1 loss reflects the selection bias inherent in enucleation-based cohorts, which are enriched for large, molecularly high-risk tumors. This study provides the first comprehensive BAP1 immunohistochemical data from Croatia, contributing to the growing evidence that enucleation cohorts represent a distinct, biologically high-risk subgroup in which BAP1 immunohistochemistry offers limited discriminatory value. The extended follow-up of 11.2 years confirms the prolonged natural history of UM. Future multi-center studies incorporating molecular validation and diverse treatment modalities are needed to establish the prognostic utility of BAP1 across the full spectrum of UM disease.

These findings confirm that MBD4 is an important predisposing gene to uveal melanoma in the French population. This reinforces a strategy of broad patient screening given the therapeutic implications and the consequences of genetic counseling.

Furthermore, the drug-gene interaction network consisted of 20 potential candidate drugs. In conclusion, the present integrated analysis offers a comprehensive understanding of the potential role in RB, providing valuable insights into the molecular mechanisms and potential therapeutic targets for this childhood ocular tumor.

However, spontaneous regression of choroidal nevus is exceedingly rare, with only 2 cases previously reported in the literature. The underlying mechanism is presumed to involve an immune-mediated response driven by melanocyte-specific T lymphocytes, predominantly cytotoxic CD8+ T cells.

Our study demonstrates for the first time that BAI can inhibit CM malignant progression by modulating the PI3K/AKT/mTOR signaling pathway. This study suggests that BAI may be used as a promising anti-tumor agent for further treatment of CM.

P2, N=15, Completed, St Vincent's Hospital, Sydney | Active, not recruiting --> Completed

P1, N=1, Terminated, Emory University | Active, not recruiting --> Terminated; Slow accrual

Furthermore, the anti-tumor effect of CM-Thy was validated through various mechanisms involved in tumor formation such as angiogenesis and vasculogenic mimicry. Interestingly, the results from visible light experiments conducted in vitro also substantiated the remarkable therapeutic efficacy of this system for refractive eye disorders while providing innovative ideas for cross-species biological interventions.

Although agents such as lenalidomide and Bruton's tyrosine kinase(BTK) inhibitors have demonstrated efficacy in relapsed/refractory (R/R)PVRL, their role in treatment-naïve patients remains unclear. In conclusion, the combination of Orelabrutinib, rituximab, and intravitreal MTX is a feasible therapeutic strategy for PVRL. Our findings may contribute to a potential paradigm shift in the management of this rare disease.

Additionally, we discuss its interactions with autophagy, cellular senescence, and cell death, exploring its potential as a therapeutic target in inflammatory and neoplastic eye conditions. Finally, we identify key unresolved questions and outline future research directions aimed at exploiting cGAS-STING modulation for precision therapies in vision-threatening diseases.